Durham-based Serenex, Inc. (www.serenex.com), has inked a research agreement with Roche, a Swiss-based drug discovery company, which involves the utilization of Serenex's chemoproteomics technologies within Roche's drug discovery program. The companies plan to jointly evaluate how Serenex's technologies may impact the identification of the most appropriate compounds to advance through drug discovery and development.
The agreement provides Roche with access to Serenex's unique Proteome Mining and Functional Proteome Fractionation technologies. Under the terms of the collaboration, Roche will supply Serenex with small molecule, drug-like compounds. Serenex will use its technologies to screen the Roche compounds against thousands of protein targets simultaneously.
Serenex has been a CED member since 2002.